Briumvi (ublituximab-xiiy)
Briumvi is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Pregnancy testing is recommended for females of reproductive potential prior to each infusion with Briumvi.
Indication:
Relapsing form of Multiple Sclerosis
Clinically Isolated syndrome
Relapsing-remitting disease
Active secondary progressive disease in adults
Infusion Duration:
Dose 1: 4-hour infusion/1 hour post infusion observation
Dose 2:1-hour infusion/1 hour post infusion observation
Subsequent dosing every 24 weeks-1 hour infusion
Frequency:
Dose 1-Day 1
Dose 2-Day 15
Subsequent dosing every 24 weeks